LUCIUS 卢修斯 卡匹色替 卡帕塞替尼 Capivasertib乳腺癌

卡匹色替

美国FDA批准上市产品,疗效确切

另译为

卡帕塞替尼

卢修斯制药(老挝)有限公司出品
老挝国家食药监局批准上市

Capivasertib

老挝国家药检所检测认证

Composition:

Each film-coated tablet contains Capivasertib .. 200 mg

Indicationi

乳腺癌

LuciCapiva is a kinase inhibifor indicaled, Il

LUCiUS

combination with fulvestrant for the treatment of ad

PHARMACEUTICALS

rmone receptor (HR)-positive, human

Pucrmlal growth factor recepros
locally advanced or mataetstee kee ea

or more PIK3CA/AKTIPTEN-alterations as detecie
by an FDA-aporoved tast followine proes

LuciCapiva

docrine-bascd regimen in tue metastale
gesion on at

eiing of fecarrence on or within 12 months of comnleting
adjuvant therapy.
Scicet patients for the treatment of HR-positive,

FDA批准

TEKi-negative advanced or metastatic breast cance

Capivasertib Tablets

Witn LuciCapiva based on the presen

presence of one or mors

przegenetic alterations in tumor tissue
LWAKTUPTEN.
. Recommendad Tans
comkinann 5 700 mg orally twice daily in

200mg

with Fulvestrant, with or without food, for
4 days followed by 3 davs off.
Storage: in a dry place and store at 20C to 25C
Keep medicine out of reach of Children. Do not admitiste

Rx only

LuciCaprva during Pregmancv and Lactatiom
PLEASE SEEDACKAGEINSER
Manufactured and Marketed by:

权威认证

LUCIUS

gvillage, Xaythany district, Vientian
Capital, Laos
www.luciuk
Warning: Tohe soldhuan
o be sold by retail on prescrintion
ol registered pnysicians only, and as directerl
oy the physician.

64 Tablets

口碑质量

适应症:
卡帕塞替尼与氟维司群联合适用于治疗激素受体(HR)阳性、人类
表皮生长因子受体2(HER2)阴性、局部晚期或转移性乳腺癌的成
年患者,这些患者有一种或多种PIK3CA/AKT1/PTEN改变,在转
移性乳腺癌中接受至少一种内分泌治疗方案后出现进展,或在完
成辅助治疗时或完成辅助治疗后12个月内出现复发。
推荐剂量:
每日口服两次,每次400毫克,可与食物同服或单独服用,连续服
用4天,然后停药3天。